🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Digestive Cancer

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Enfortumab Vedotin SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC NCT07284992Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer NCT07692204Phase 21 site📍 Shanghai Sanofi · Tests: SAR445877 Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) A Study of Tucatinib and Trastuzumab in People With Rectal Cancer NCT05672524Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Trastuzumab, Tucatinib Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818Phase 369 sites📍 Brussels📍 Brussels📍 Edegem UNICANCER · Tests: Futibatinib, Ivosidenib, Zanidatamab, Trastuzumab, Neratinib Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps NCT05080673NA493 sites📍 Fairbanks📍 Goodyear📍 Kingman NRG Oncology · Tests: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer NCT07315854Phase 21 site📍 Beijing Beijing Friendship Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer NCT07194005Phase 21 site📍 Shanghai Fudan University · Tests: Disitamab vedotin(RC48), Sintilimab, S-1, Oxaliplatin Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy NCT06586242Phase 21 site📍 Xi'an Xijing Hospital · Tests: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 NCT07595874Phase 211 sites📍 Goodyear📍 Corona📍 Duarte City of Hope Medical Center · Tests: Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Magnetic Resonance Imaging Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. NCT06940388Phase 22 sites📍 Mainz📍 Petah Tikva brenner baruch · Tests: Tislelizumab, Total neoadjuvant therapy (TNT) A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) NCT05332002Phase 26 sites📍 Hamilton📍 Lakewood📍 Long Branch Rutgers, The State University of New Jersey · Tests: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer NCT07108127Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer NCT04592211Phase 1, Phase 21 site📍 Seoul Yonsei University · Tests: olaparib+pembrolizumab+paclitaxel Predicting Gastric Cancer Response to Chemo With Multimodal AI Model NCT06451393n/a1 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Neoadjuvant chemotherapy with radical tumor resection surgery
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy